BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 36346100)

  • 21. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small cell lung cancer; recent advances of its biology and therapeutic perspective.
    Hayashi R; Inomata M
    Respir Investig; 2022 Mar; 60(2):197-204. PubMed ID: 34896039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of small cell lung cancer: recent advances.
    Chu X; Han C; Su C
    Curr Opin Oncol; 2022 Jan; 34(1):83-88. PubMed ID: 34698669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Therapeutic Options for Small Cell Lung Cancer.
    Canova S; Trevisan B; Abbate MI; Colonese F; Sala L; Baggi A; Bianchi SP; D'Agostino A; Cortinovis DL
    Curr Oncol Rep; 2023 Nov; 25(11):1277-1294. PubMed ID: 37870696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. m
    Zhang Z; Zhang C; Luo Y; Wu P; Zhang G; Zeng Q; Wang L; Yang Z; Xue L; Zheng B; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
    BMC Med; 2021 Nov; 19(1):284. PubMed ID: 34802443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update 2021: Management of Small Cell Lung Cancer.
    Tariq S; Kim SY; Monteiro de Oliveira Novaes J; Cheng H
    Lung; 2021 Dec; 199(6):579-587. PubMed ID: 34757446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
    Badin F
    Cancer Treat Res Commun; 2024; 39():100803. PubMed ID: 38490092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
    Das M; Padda SK; Weiss J; Owonikoko TK
    Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
    Yang Y; Ai X; Xu H; Yang G; Yang L; Hao X; Yang K; Mi Y; Wang G; Zhang S; Lei S; Wang Y
    Thorac Cancer; 2022 Dec; 13(23):3295-3303. PubMed ID: 36218023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Horn L; Reck M; Spigel DR
    Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.
    Lorenzi M; Resi MV; Bonanno L; Frega S; Dal Maso A; Ferro A; Guarneri V; Pasello G
    Front Immunol; 2024; 15():1308109. PubMed ID: 38348046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in pharmacotherapy of small cell lung cancer.
    Kalemkerian GP
    Expert Opin Pharmacother; 2014 Nov; 15(16):2385-96. PubMed ID: 25255939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for small cell lung cancer: established applications and novel approaches.
    Scott SC; Hann CL
    Clin Adv Hematol Oncol; 2021 Oct; 19(10):654-663. PubMed ID: 34637432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting DNA damage in SCLC.
    Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F
    Lung Cancer; 2017 Dec; 114():12-22. PubMed ID: 29173760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy.
    Hao Z; Sekkath Veedu J
    Clin Lung Cancer; 2022 Jan; 23(1):14-20. PubMed ID: 34656433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
    Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions.
    Zhang C; Zhang C; Wang K; Wang H
    J Transl Med; 2023 Jul; 21(1):468. PubMed ID: 37452395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on new drugs in small cell lung cancer.
    Horn L; Castellanos EL; Johnson DH
    Expert Opin Investig Drugs; 2011 Apr; 20(4):441-5. PubMed ID: 21395484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small cell lung cancer: a slightly less orphan disease after immunotherapy.
    Remon J; Aldea M; Besse B; Planchard D; Reck M; Giaccone G; Soria JC
    Ann Oncol; 2021 Jun; 32(6):698-709. PubMed ID: 33737119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.